UPPSALA, October 8, 2012 -- Isconova AB’s partner The Jenner Institute at Oxford University (U.K.) has received approval from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK to initiate a phase I study
with a malaria vaccine candidate, containing Isconova’s proprietary adjuvant Matrix-M™.
The first volunteer has received the vaccine that is a combination of a viral vector encoding a
malaria antigen developed by Oxford mixed with Matrix-M™.
The Jenner Institute is a leader in the development of several new vaccines many of which are in
phase II clinical development. Isconova and Jenner Institute have a strategic collaboration, where
the lead project focuses on the development of a malaria vaccine with a high level of efficacy. Each
year, over 200 million people are affected by malaria, with almost 700 thousand deaths from the
disease in 2010 alone1
. There are currently no malaria vaccines available on the market.
Sven Andréasson, CEO of Isconova AB, commented;
“The approval to initiate this study represents another validation of quality for Isconova. The study is
the fourth phase I study to be initiated with Matrix-M™, the diverse diseases targeted by the studies
demonstrate the broad potential of Matrix-M™ adjuvant in human vaccines. We are proud to
collaborate with Jenner Institute and very pleased that they have selected Matrix-M™ to be an
important part of their malaria program.”
Prof Adrian Hill, Director of the Jenner Institute, commented;
“It has proven very challenging to develop a vaccine against malaria and lots of different approaches
have been tested. After a thorough evaluation of several adjuvants pre-clinically, we selected Matrix-
M™ for this program based on the strong immune responses elicited in these preclinical studies and
new findings on its suitability for use with viral vectored vaccines. This trial represents an important
opportunity to test the use of a potent adjuvant with this type of vaccine in the clinic.”
The phase I study will include approximately 25 volunteers and is planned to be completed by mid-
2013. The study aims to evaluate the safety and immunogenicity of the malaria vaccine candidate.
The trial is sponsored by the University of Oxford and receives funding support from the National
Institute for Health Research Oxford Biomedical Research Centre at The Oxford University Hospitals
NHS Trust and the University of Oxford.
Provided that the development will be successful and lead to a partnership with a vaccine company
for future commercialization, future revenues will be shared between the partners.
For more information, please contact:
Sven Andréasson, CEO of Isconova, phone +46 701 60 60 60, e-mail: email@example.com
Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of
vaccine systems, and the company develops novel vaccines together with partners in the human and
veterinary markets. The first vaccine using Isconova’s Matrix technology was launched in the
veterinary market in 2006. In the human vaccine market, a number of vaccines are under
development with Isconova’s third generation nano-particle, Matrix-M™. The Company is
headquartered in Uppsala, Sweden.
Isconova AB is listed on NASDAQ OMX First North (ticker: ISCO). Pareto Öhman AB is the Company’s
Matrix-M™ is Isconova’s patented adjuvant product for use in human and veterinary vaccines,
antibody production and immunological research.
Adjuvants enhance the efficacy of a vaccine or drugs while maintaining safety. Adjuvants increase the
vaccine's ability to produce antibodies and induces a cellular response that is important for modern
About The Jenner Institute
The Jenner Institute is a research partnership between the University of Oxford and the Institute for
Animal Health. The Institute focuses on the parallel development of human and veterinary vaccines
against major global diseases – from early-stage research through to clinical trials. www.jenner.ac.uk
About The National Institute for Health Research
The National Institute for Health Research (NIHR) is funded by the UK Department of Health to
improve the health and wealth of the nation through research. Since its establishment in April 2006,
the NIHR has transformed research in the NHS. It has increased the volume of applied health
research for the benefit of patients and the public, driven faster translation of basic science
discoveries into tangible benefits for patients and the economy, and developed and supported the
people who conduct and contribute to applied health research. The NIHR plays a key role in the
Government’s strategy for economic growth, attracting investment by the life-sciences industries
through its world-class infrastructure for health research. Together, the NIHR people, programmes,
centres of excellence and systems represent the most integrated health research system in the
world. For further information, visit the NIHR website www.nihr.ac.uk. The views expressed in this
news release are those of the authors and not necessarily those of the NHS, the NIHR or the
Department of Health.